Dan Bloomfield has more than 20 years in drug development, initially at Merck and most recently at Cardurion Pharmaceuticals. Dr. Bloomfield joined Cardurion in May 2017 as its first CEO after a diverse 14-year career at Merck & Co. (NYSE: MRK), which included leadership roles in early and late clinical development and cardiovascular discovery. He was actively involved in business development, acquisitions, and numerous licensing opportunities and spent a year as Chief of Staff for Merck’s CEO, Ken Frazier. Dr. Bloomfield’s career at Merck culminated as SVP and Therapeutic Area Head for Cardiovascular, Diabetes, Endocrine, and Women’s Health Programs and he was responsible for the central coordination and strategic oversight of Merck’s R&D organization in China across all therapeutic areas.
In addition to his executive duties, Dr. Bloomfield was a founding member and co-chair of the Cardiac Safety Research Consortium (a public-private partnership with the FDA, academia and industry) and served as Rapporteur for the ICH E14 implementation working group for nine years.
After finishing a BA in Chemistry at Haverford College, Dr. Bloomfield earned a master’s degree in Social Anthropology at Oxford University as a Rhodes Scholar. Upon his return to the US, he attended Harvard Medical School and subsequently did his Internal Medicine and Cardiology training at Columbia before joining the faculty. As an Associate Professor his academic research was supported by grants from the NIH (K08, R01, K24), multiple foundations, and industry.